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Bones as an alive organ consist of about 70%mineral and 30% organic component. About 200 million people are suffering from
osteopenia and osteoporosis around the world. *ere are multiple ways of protecting bone from endogenous and exogenous
risk factors. Planned physical activity is another useful way for protecting bone health. It has been investigated that arranged
exercise would effectively regulate bone metabolism. Until now, a number of systems have discovered how exercise could help
bone health. Previous studies reported different mechanisms of the effect of exercise on bone health by modulation of bone
remodeling. However, the regulation of RANKL/RANK/OPG pathway in exercise and physical performance as one of the most
important remodeling systems is not considered comprehensive in previous evidence. *erefore, the aim of this review is to
clarify exercise influence on bone modeling and remodeling, with a concentration on its role in regulating RANKL/RANK/
OPG pathway.
1. Introduction
Bones as an alive organ consist of about 70% mineral and
30% organic material. Calcium and phosphorous crystals,
hydroxyapatite, and some ions such as sodium, fluoride,
and magnesium are constituents of the mineral part. *e
organic part contains mostly collagen fiber and, in a lower
amount, glycoproteins and proteoglycans [1]. *e skeleton
has several roles in the body such as protecting internal
organs, frame of the body, and safe storage for some vital
minerals like calcium. In contrast with what it seems,
bones are a vivid tissue which is in turnover all the time [2].
About 200 million people are suffering from osteopenia
and osteoporosis around the world; approximately 1 out of
3 women and 1 out of 5 men older than 50 years old have
some forms of bone abnormalities [3]. From the pop-
ulation aging, it has been estimated that the prevalence of
bone diseases would rise up in the near future. In the
United States of America, it is estimated that bone dis-
orders would increase 2.4 times in women and 3.1 times in
men until 2050 [4].
Bones have various types of cells including osteoclasts,
osteoblasts, osteocytes, and bone lining cells [5, 6]. Os-
teoblasts are originated from hematopoietic stem cells
(HSCs, macrophage lineage of hematopoietic stem cells),
and osteoclasts are originated from mesenchymal stem
cells (MSCs) via some stages such as osteoprogenitors and
preosteoblasts [7]. Fundamentally, bone modeling and
remodeling include osteoclasts function in the removal of
the bone surface and osteoblasts function on precipitating
new matrix in them [8, 9]. *is process is responsible for
protecting skeleton function and fracture restoring. Any
kind of defect in bone turnover coordination would result
in bone diseases such as Paget’s disease, fibrous dysplasia,
osteoarthritis, osteoporosis, and fragility fractures
[10–13].
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Osteoclasts are the major cells in charge of bone re-
sorption. *ey are positioned on the surface of bones and
form trenches by their function. Activated osteoclasts release
proteolytic enzymes which destroy connective tissues in
bones. *ey also secrete some acids that resolve the mineral
part of bones [14].*rough the different stages of osteoblasts
differentiation, the level of some biomarkers, which are
known as osteogenic markers, changes significantly. Among
these markers, osteocalcin (OCL), Runx2, alkaline phos-
phatase, and osterix (Osx) can be named. On the other hand,
for modulating monocyte-to-osteoclast differentiation, os-
teoblasts would release osteoprotegerin (OPG) and receptor
activator of NF-kB ligand (RANKL), as well as macrophage
colony-stimulating factor (M-SCF) [7, 15, 16]. RANKL/
RANK,Wnt/b-catenin, and Jagged1/Notch1 are 3 important
pathways modulated by osteoblasts which affect the bone
mass density via the regulation of osteoblasts and osteoclasts
functions [8]. In the RANKL/RANK/OPG pathway, RANKL
binds to RANK as its receptor and eventually leads to os-
teoclast precursor maturation. Osteoprotegerin is known as
a decoy receptor for RANKLwhich prevents RANKL-RANK
binding and the following reactions [17].
*ere are several risk factors for bone health such as
aging [18], estrogen deficiency, inflammation [14], metabolic
diseases, improper diets [19], kidney dysfunction [20], side
effects of some drugs like glucocorticoids [21], and oxidative
stress [22]. *ere are various ways to protect the skeleton
from disease and resorption or at least delay the onset of
such disorders. For example, physical activity, healthy diets,
and medical intervention can help the prevention of age-
related bone loss or osteoporosis [18]. Several medications
like bone resorption inhibitors and bone formation stim-
ulators are in a postmenopausal treatment lineup [23].*ese
include bisphosphonates (e.g., alendronate) [24], strontium
ranelate [25], denosumab (RANKL inhibitor) [26], and PTH
[27]. A limitation in this kind of treatment is the risks of
complications such as fever ormuscle pain [28, 29]. Having a
proper regimen that is nutrient-dense is one of the major
strategies in saving and augmenting bone mass. Vitamin D,
calcium, phosphorus, magnesium, zinc, and copper are
some examples of necessary nutrients for skeleton health
[4, 30, 31].
Planned physical activity is another useful plan for
maintaining optimal bone health. It has been suggested that
planned exercise would effectively regulate bone metabolism
[29, 32]. Some studies have reported that exercise may post-
pone the beginning of osteoporosis by improving peak bone
mass within adolescence [33, 34]. *e exact mechanism by
which exercise improves bone health is not clear yet. However,
it has been accepted that increasing muscle mass and me-
chanical stress in bones results in boosting osteoblasts activities
[35–37]. Previous studies reported different mechanisms
covering the effect of exercise on bone health by modulation of
bone remodeling. However, the regulation of RANKL/RANK/
OPG pathway as one of the most important remodeling sys-
tems is not considered comprehensive in previous reports.
*erefore, the aim of this review was to clarify exercise in-
fluence on bone modeling and remodeling, with a concen-
tration on the role of the RANKL/RANK/OPG pathway.
2. The RANK/RANKL/OPG Pathway
*e RANKL/RANK/OPG system is known for its roles in
osteoclasts maturation, bone modeling, and bone remod-
eling. Receptor activator of NF-kB (RANK), receptor acti-
vator of NF-kB ligand (RANKL), and osteoprotegerin
(OPG) are the main components of this signaling system.
Interestingly, taking part in bone hemostasis is not the only
effect of the RANKL/RANK/OPG pathway [2].
RANKL (also known as OPGL, ODF, and TRANCE), as
a homotrimeric protein, is produced by osteoblasts and
some other cells like activated T cells [38–40]. *e secreted
type of RANKL is a result of proteolytic division or alter-
native splicing on the membrane form [41]. Matrix
metalloproteases (MMP3 or 7) and ADAM (a disintegrin
and metalloprotease domain) are responsible for RANKL
proteolytic cleavage [42, 43]. RANKL, which is a secretion of
preosteoblasts, osteoblasts, osteocytes, and periosteal cells
[44–46], make RANK activated, which is expressed by os-
teoclasts and its precursors [47]. RANKL has assignments
for stimulating preosteoclasts’ differentiation [48], adher-
ence osteoclasts to bone tissue [49] and their following
activation [48, 50], and their maintenance [51]. Pre-
osteoclasts combine together and make a multinuclear cell
which is affected by RANKL [8] not clear.
RANKL can be also produced by other organs such as
thymus, lymph nodes, lung, and mammary glands, as well as
the spleen and bone marrow [40]. RANKLmight be released
from epithelial cells in the lobules of mammary glands
during pregnancy. Based on an animal study, RANKL helps
in hyperplasia of these epithelial cells which is necessary for
lactation and milk production [52].
RANK is also a homotrimeric transmembrane receptor
from the TNF family. Its primary expression is limited to
OPCs, dendritic cells, and mature osteoclasts [38]. RANK
does not have innate protein kinase activating activity as
other TNF family receptors have. All of the TRAFs 2, 5, and 6
bind to RANK but only TRAF 6 is required for bone health
[53–56]. Aside from bone cells, RANK would be expressed
by some carcinoma cells, such as breast cancer or prostate
cancer, and also expressed in the mammary gland
[52, 57, 58]. One of the roles of RANK that has received
attention is its role in cancer cell proliferation; this makes
RANK interesting in future therapy for cancers [57].
In addition to osteoblasts, there are plenty of cells that
could express osteoprotegerins, such as the heart, liver,
spleen, and kidney. A recent study suggested that B cells are
in charge of 64% of bone marrow OPG expression [59]. As a
TNF superfamily, OPG plays an anti-osteoclastogenesis role
with binding to RANKL [60]. OPG takes part as a decoy
receptor for RANKL and inhibiting RANKL-RANK binding
through it. In fact, several agents that induce RANKL in-
fluence OPG regulation [61, 62]. Recent studies have shown
that increases in plasma OPG levels in postmenopausal
women lead to bone mass reinforcement [50]. Furthermore,
in an experiment conducted by the use of mice, OPG was
found to be a protector of large vessels from calcification
[49]. Moreover, OPG has been suggested as an inhibitor of
atherosclerotic plaque calcification [63].
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3. RANKL/RANK/OPG Pathway and
Bone Metabolism
Before the discovery of the RANKL/RANK/OPG signaling
pathway in the 1990s, it was suggested that some agents
expressed by osteoblasts are responsible for osteoclasts
activation. But it was unexpected that these agents have
been members of the TNF superfamily and they could have
more functions than the bone turnover in the body [2].
Obviously, it is osteoblasts’ task to recruit osteoclasts for
bone resorption sites. Also, osteoblasts could regulate bone
resorption by secreting OPG and RANKL. In fact, RANKL
embedded from osteoclasts binds to its receptor (RANK)
on the surface of OCPs and increases osteoclasts differ-
entiation and mature osteoclasts. OPG could bind to
RANKL and inhibits osteoclasts differentiation which
means upregulation of OPG/RANKL ratio preventing
osteoclastogenesis [64, 65]. Similar to other TNF family
receptors, RANK does not have any innate protein kinase
activities to regulate the signaling pathway. TRAF 6 is the
only essential TRAF, among all TRAFs, that bind to RANK
for regulating OCPs and osteoclasts activities. To support
this claim, several studies have reported that a deficiency in
TRAF 6 results in the development of osteoporosis
[8, 53–55].
Probably the conclusive determinant in bone resorp-
tion is the RANKL/OPG ratio. Most of the time, both
RANKL upregulation and OPG downregulation lead to
bone loss [66]. *ere are several endogenous factors that
affect the control of the RANKL/RANK/OPG system in-
cluding some cytokines (TNF-a, IL-1, IL-6, IL-4, IL-11, and
IL-17), hormones (vitamin D, estrogen, and glucocorti-
coids), and mesenchymal transcription factors [13, 67].
OPG is regulated by not only cytokines, hormones, and
growth factors but also by Wnt/b-catenin [8, 68–70]. For
osteoclast precursors conversion to mature osteoclasts,
c-Fos is needed which is an activated transcription factor
for RANKL [2, 71]. sRANKL is the soluble form of RANKL
which appears in plasma. Elimination of RANKL and
RANK in animal studies shows a major effect in inhibiting
bone mass loss and osteoporosis [72]. Based on clinical
observations, enhancing OPG concentrations in plasma
leads to bone mass density augmentation in postmeno-
pausal women [73].
In so many skeleton and nonskeletal disorders, alter-
ations in RANKL and OPG proteins and their mRNA are
observable [66]. Enhancement in ROS (reactive oxygen
species) production through the function of NADPH oxi-
dase enzymes controls osteoclastogenesis via regulating
RANKL expression [14, 74]. Also, proinflammatory cyto-
kines which increase in inflammatory conditions lead to the
overexpression of RANKL by T cells that correlate with
lower bone mass density (BMD) [56, 75]. In some patho-
logical conditions like postmenopausal osteoporosis or ar-
thritis rheumatoid which influenced hormones and
cytokines level, bone resorption would significantly increase.
*ese types of diseases would increase bone remodeling
mostly through RANKL and M-CSF expression enhance-
ment [2, 9].
Juvenile Paget disease is diagnosed via osteopenia,
fractures, fast remodeling in woven bones, and development
of bone deformities. In two Paget disease cases, depletion in
OPG has been reported [38, 76]. Idiopathic hyper-
phosphatasia is also an autosomal osteopathic medicine and
alterations in OPG level have a vital role in this disease. In
this regard, OPG inactivation has been observed in some
clinical trials [38, 69]. RANK signaling pathway is involved
in a giant cell tumor of bone (GCTB) which is a rare and
painful cancer. *is cascade leads to excessive bone re-
sorption andmetastasis in these patients [77]. In rheumatoid
arthritis, the inflammation advent results in overexpression
in RANKL and subsequently bone-weakening [78].
3.1. Exercise and Bone Health. Exercise or planned physical
activity is supposed to contribute to maintaining optimal
health and healthy body weight [79, 80]. Exercise could
indicate a “rejuvenating effect” and possibly prevent age-
related skeleton disorders and bone resorption [18, 81].
Exercise has several advantages in protecting body health
particularly bone modeling and remodeling [80]. *e ability
for bones to adjust with mechanical force and stress has been
observed in the late 19th century [82].
Mechanical load is one of the most important agents for
bone mass density enhancement. *e Mechanostat theory,
which is first mentioned by Frost, expresses that bones have
their own innate biological system to induce bone forma-
tion, in response to mechanical forces. *is system includes
bone cells, major osteocytes which are impressed by me-
chanical strain, transmitting it to the osteoclasts and oste-
oblasts and resulting in regulation of the skeleton
homeostasis [37, 83, 84]. It has been accepted that me-
chanical forces help promote bone mass and strength. In-
terestingly, the skeleton could discriminate between internal
force and strain-driven [85]. Osteoblasts, osteoclasts, and
other bone cells are influenced by various endogen and
exogen factors like cytokines. Proinflammatory and anti-
inflammatory cytokines have major roles in skeleton
modeling and remodeling [39]. Studies have shown that
joint disorders like arthritis could make asymmetry pro- and
anti-inflammatory cytokines, leading to bone loss [39, 86].
Exercise might increase anti-inflammatory cytokines and
cause improvement in inflammatory cytokines [87, 88].
Also, mechanical load as an exercise regulates collagen
synthesis during bone formation [89]. Muscle tension is
transferred to the bones and leads to provoking osteoblasts
proliferation [90]. In contrast, the lake of exercise,
weightlessness, or bedridden would reduce osteoblasts ac-
tivity and increase osteoclasts function [91].
Exercise is categorized into 6 classes: static weight-
bearing exercises such as single-leg standing, high-impact
weight-bearing exercises like running or dancing, low-im-
pact weight-bearing exercises such as Tai Chi, high-impact
non-weight-bearing exercises, low-impact non-weight-
bearing exercises like swimming, and combination exercises
[37, 92]. Investigations have indicated that regular physical
activity with long duration and moderate intensity would
decrease bone resorption and increase bone mass in both
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healthy and pathologic subjects [80]. Bone health would
improve through weight-bearing exercises and helps bone
density in growth, promoting bone health in aging [93–95].
In a 12-month clinical trial, postmenopausal inactive women
with high doses of exercise had a greater bone mass density
compared to women with moderate-dose exercise. *is
effect remained for almost a year after finishing study [29].
Intensive weight-bearing exercise may propagate P1NP,
BAP, OPG, phosphate, and PTH levels [65, 96].
Exercise brings a cycle of reactions in the hypothalamus-
hypophysis-adrenal line or hypothalamus-hypophysis-go-
nad line. *ese reactions stimulate some hormone expres-
sions which help MSC differentiation to osteoblasts,
including growth hormone, PTH, PGE2, and thyroid hor-
mones [65, 97–100]. Sclerostin, a major role in bone for-
mation, is a protein expressed by osteocytes. In fact,
sclerostin supports bone mass by prohibiting the Wnt/B-
catenin pathway.Wnt is a signaling pathway that proliferates
osteoprogenitor and minimizes mature osteoblasts apo-
ptosis. Exercise and the followed mechanical load lead to the
reduction in bone sclerostin synthesis. Afterward, osteo-
blastic bone formation increases and osteoclastic bone loss
decreases [37, 101]. *ere is some strong evidence that
demonstrated exercise decline mRNA levels of markers from
bone resorption like TRAP, cathepsin-K, and calcitonin
receptors [102]. Moreover, participating in exercise could
increase some osteogenic markers like OCL, Runx2, Osx,
BAP, BMP2, and collagen type 1 in osteoblasts [15, 103–105].
It has been demonstrated that BAP andOCL, which are bone
formation markers, are upregulated and TRAP (tartrate-
resistant acid phosphatase), which is a bone resorption
marker, is downregulated within an 8-week exercise plan in
women [65, 103].
It has been shown that exercise promotes bone health
through RANKL/RANK/OPG pathway regulation too [65].
3.2. Favorable Effects of Exercise on Bone Health by RANKL/
RANK/OPG Regulation. Figure 1 presents the details of the
positive role of exercise in bone remodeling. Osteoblasts and
osteoclasts are responsible for bone formation and bone
resorption, respectively. So the effects of exercise on these 2
types of cells would help understand the association between
exercise, bonemodeling, and bone remodeling [88]. Exercise
is responsible for the suppression in osteoclastogenesis and
bone remodeling, which is mediated through the OPG/
RANKL pathway released by osteoblasts, osteocytes, and
MSCs [65].
*ere are multiple animal studies investigating the effect
of chronic exercises on the pathway. In a study conducted
using rats with CKD, the expression of RANKL and
osteocalcin increased after endurance treadmill exercise
[106]. Another study demonstrated the effects of exercise on
glucocorticoid-induced osteoporotic that was investigated in
rats. *e results of this study confirmed that RANKL and
RANKL-induced bone loss would be inhibited by vibration
and treadmill training [107]. It was suggested that the
treadmill and vibration stimulation exercise leads to a de-
crease in RANKL expression and an increase in OPG ex-
pression in the glucocorticoid-induced osteoporotic rats
[107]. OPG and RANKL were meaningfully increased in
response to 5-minute physical activity. In this study, which
was performed on prednisolone-induced osteoporotic rats
cells, treadmill and vibration platform training were used as
examples of physical training. *e results of the group
treated with treadmill and vibration stimulation training
indicated a subsequent decrease in RANKL and an increase
in OPG levels [107]. Some limited animal studies reported
beneficial effects of acute exercise on the pathway. Decreased
RANKL levels and increased OPG levels have been observed
in an experiment using acute training murine MC3T3-E1
osteoblasts [108]. In a chronic exercise study which was
conducted in rats, an enhancement in the OPG/RANKL
ratio was shown because of a decrease in RANKL expression
[104]. On the other hand, an in vitro study has illustrated
that mechanical strain could lead to abundance in OPG
levels and decreases in M-CSF levels without alterations in
RANKL levels in human osteoblasts [109]. Rubin et al.
suggested that mechanical load could cause a reduction in
RANKL, resulting in strong protection of bone loss and
osteoclast proliferation [110].
Several previous studies reported the influence of acute
exercises on the RANKL/RANK/OPG pathway. Scott et al.
reported that acute endurance exercise causes an increase in
levels of BAP and OPG in healthy men [96]. High-intensive
acute exercise would enhance OPG and RANKL instantly.
Also, this study has shown that 5-minute exercise increases
IL-1a, IL-1B, IL-6, and TNF-a and 1-hour exercise brought
Increases OPG
Decreases
Exercise
RANK
RANKL
Precursor
osteoclast
Osteoblast
Osteoblast
Bone resorption
Figure 1: Interaction of exercise and RANKL/RANK/OPG biomolecular pathway. OPG: osteoprotegerin; RANK: receptor activator of
nuclear factor κB; RANKL: receptor activator of NF-kB ligand.
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Table 1: General characteristics of the studies investigating the effects of exercises on RANKL/RANK/OPG regulation. ALP: alkaline
phosphatase; BAP: bone alkaline phosphatase, OPG: osteoprotegerin; RANK: receptor activator of nuclear factor κB; RANKL: receptor
activator of NF-kB ligand.
Study name,
year Exercise type Treatment time
Species/population/
condition Significant outcome
Scott et al.
2011 [96]
Acute, weight-bearing endurance
exercise 8 days Healthy men OPG↑, BAP↑
Kish et al.
2015 [121] Plyometric exercise
5 minutes, 1 hour, and
finally 24 hours after
exercise
Healthy boys and men OPG↑, ALP↑
Bergstro¨m
et al. 2011
[115]
Physical training (fast
walking + aerobic training) 1 year
Postmenopausal
women OPG↑, RANKL↔, sclerostin↔
Rubin et al.
2000 [110]
Mechanical strain by a flexcell bioflex
instrument 3 days
Murine bone stromal
cells RANKL↓
Notomi et al.
2014 [104] Resistance training 8 weeks
Male Sprague Dawley
rats
RANKL↓, OPG↔, OPG/
RANKL↑
Mezil et al.
2015 [88] High-intensity low-impact exercise
5 minutes after
exercise Male university
students
ALP↑, OPG↑, RANKL↑
1 hour after exercise ALP↑
24 hours after exercise ALP↑
Troib et al.
2016 [106] Endurance treadmill exercise 4 weeks
Young and growth-
retarded chronic kidney
disease rats
RANKL↑, Osteocalcin↑
Pichler et al.
2013 [107]
Treadmill and vibration stimulation
training NS Osteoporosis rats OPG↑, RANKL↓
Esen 2009
[116] High-intensity walking (n� 14) 10 weeks Middle-aged men OPG↔, sRANKL↓
Esen 2009
[116] Moderate-intensity walking (n� 13) 10 weeks Middle-aged men OPG↔, sRANKL↔
Ziegler et al.
2005 [111]
Endurance running distance of
42.195 km
*e first 30 minutes of
finishing the run Long-distance runners sRANKL↓, OPG↑
Ziegler et al.
2005 [111]
Endurance running shorter distance of
15.8 km
*e first 30 minutes of
finishing the run Long-distance runners sRANKL↓, OPG↔
Tang et al.
2006 [108]
Cyclic tensile strain using a flexercell
strain unit with 6%, 12% or 18%
elongation
24 hours Murine MC3T3-E1osteoblasts
OPG↑, OPG mRNA
expression↑, sRANKL↓,
RANKL mRNA expression↓
(magnitude-dependent)
Kim et al.
2019 [113] Combined exercise 12 weeks Healthy college females
OPG↔, RANKL↔, RANKL/
RANK/OPG signaling mRNA
expression↔
Saunders
et al. 2006
[109]
Small-scale loading machine that
imparts via bending 3 hours
Osteoblastic MG-63
cells
OPG↑, RANKL↔, OPG/
RANK ratio↑
Kim et al.
2017 [112]
Acute exercise of high (80% VO2max)
intensity
Immediately after and
then recovery 60
minutes after exercise
Osteopenia elderly
women OPG↑, RANKL↔
Kim et al.
2017 [112]
Acute exercise of low (40% VO2max)
intensity
Immediately after and
then recovery 60
minutes after exercise
Osteopenia elderly
women OPG↔, RANKL↔
Marques et al.
2013 [117]
Resistance exercise accompanied by
weight-bearing exercise 32 weeks Healthy older adults
RANKL↔, OPG↔, OPG/
RANKL ratio↔
Marques et al.
2011 [118] Resistance exercise (RE) 8 months Older women
RANKL↔, OPG↔, OPG/
RANKL ratio↔
Marques et al.
2011 [118] Aerobic exercise (AE) 8 months Older women
RANKL↔, OPG↔, OPG/
RANKL ratio↔
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them back to the basic levels [88]. *e findings of another
study suggested that endurance running made a reduction in
sRANKL and an increase in OPG concentrations. *e in-
tensity in these results depends on the distance and duration
of the path [111]. After a performance period with 80%
VO2max and 40% VO2max intensity, OPG levels in serum
have increased just under high-intensity exercise conditions
in elderly women [112]. Based on a clinical trial done by
Mezil et al., the low-impact high-intensity exercise would
increase OPG, RANKL, and ALP levels in male university
students [88]. *e authors noted that, in the absence of
adequate exercise, RANKL/RANK/OPG pathway effects
would be minimal [113]. Acute training exercise with 60% or
80%VO2max intensity could not change serumRANKL and
OPG levels, nor RANKL/RANK/OPG mRNA expression in
college women [114].
In addition to acute exercise, the chronic exercises exert
similar effects on RANKL/RANK/OPG pathway. In an in-
vestigation, long-term and intensive chronic exercise causes
upregulation of OPG expression in postmenopausal women
as compared to that in sedentary cases [115]. An article re-
ported that after a 10-week high-impact walking plan, it
significantly diminished RANKL levels without significant
changes in OPG levels in middle-aged men [116]. Some
findings suggested that RANKL and OPG levels and their
expressions do not necessarily change by exercise. For ex-
ample, a 32-week resistance exercise accompanied by weight-
bearing exercise had no effect on RANKL and OPG levels and
their ratio [117]. Likewise, in older women, after 8 months of
resistance exercise or aerobic exercise, no significant changes
were observed in RANKL and OPG levels [118]. After 12
weeks of combined exercise, Kim et al. found no significant
changes in serum OPG and RANKL concentrations, nor in
RANKL/RANK/OPG signaling mRNA expression [113].
Along with animal and human adult studies, there are
several trails that include children and adolescents. *ese
studies mostly focused on acute exercises. In one of these
studies, the osteokines responses to rest and plyometric
exercises in children have evaluated. Boys and girls with 10
years old on average were included in this study and the
amounts of RANKL and OPG were measured before and
after exercise (5min, 1 hour, and 24 hours). In the pre-
exercise analysis, it turned out that boys have higher levels of
RANKL which indicated the discrimination in bone turn-
over between the two genders through the growth time. Girls
showed a reduction in RANKL through exercise and it has
kept reducingmore when they continued to exercise till 24 h.
OPG is enhanced by exercise; this enhancement is higher in
boys specifically in 5min and 1-hour exercise against girls
which indicated the increment only on 24 h level of exercise
[119].*e other survey has measured the plyometric exercise
(high-impact) effects on bones in young females and the
outcomes expressed a reduction in RANKL levels after 5-
minute exercise. It stayed lower than the basic level (pre-
exercise) until the end of 24 h exercise. However, OPG did
not change at significant levels [120]. *e finding of an
investigation demonstrated that one session of plyometric
exercise could increase both OPG and ALP (alkaline
phosphatase) in boys and young men [121]. Another study
investigated the bone mass impacts of exercise on adolescent
girls. Participants were divided into 4 groups: high-impact
exercise, medium-impact exercise, no-impact exercise, and
leisure physical activity. *e results represent no significant
variation in OPG levels among groups; we have a slight
reduction in OPG through growing just in a high-impact
group. Also, RANKL levels increased along with age except
in no-impact exercise (swimmers) which made a reduction
in RANKL [122]. *e comparison between the professional
young female trainers who exercise 12–30 hours per week
and nonathlete girls who do unplanned physical activity less
than 3 hours in a week has shown that RANKL increases
simultaneously with aging in both groups. No significant
Table 1: Continued.
Study name,
year Exercise type Treatment time
Species/population/
condition Significant outcome
Kim et al.
2018 [114]
Acute exercise of high (80% VO2max)
intensity
Immediately after and
then recovery 90
minutes after exercise
Healthy college females
RANKL↔, OPG↔, RANKL/
RANK/OPG pathway mRNA
expression↔
Kim et al.
2018 [114]
Acute exercise of moderate (60%
VO2max) intensity
Immediately after and
then recovery 90
minutes after exercise
Healthy college females
RANKL↔, OPG↔, RANKL/
RANK/OPG pathway mRNA
expression↔
Klentrou et al.
2018 [119]
Rest and following plyometric exercise
(5min, 1 h, and 24 h) 24 hours
Boys and girls (10 years
old in average)
Girls: OPG↑, RANKL↓
Boys: OPG↑, RANKL↑
Dekker et al.
2017 [120]
1 resting and 3 after exercise (5min,
1 h, and 24 h) 24 hours
Premenarcheal and
postmenarcheal girls
RANKL↓OPG↔
OPG/RANKL↑
Maı¨moun
et al. 2011
[123]
Training 12–30 h/week) professional
athlete (compared with free-time
physical activity≤ 3 h/week
(nonathlete)
— Girls (age 10–17.2years) OPG↔RANKL↑
Maı¨moun
et al. 2013
[122]
Participants are divided into 4 groups:
high-impact exercise, medium-impact
exercise, no-impact exercise, and
leisure physical activity
— Girls from 10.7 to 18.0years old OPG↔RANKL↑
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change was reported in them [123]. Table 1 displays the
characteristics of the studies investigating the effects of
different kinds of exercises on the RANKL/RANK/OPG
pathway.
Despite strong evidence for the impact of mechanical
loads on the RANKL/RANK/OPG signaling system, our
knowledge is still limited on how this pathway may con-
tribute to optimal bone health.
4. Conclusion
Based on the different studies that we reviewed, antithesis
results have appeared. In most of the studies, exercise and
physical activities promote bone health by increasing OPG
and decreasing RANKL levels. However, there are several
investigations that reported no change in OPG and RANKL
levels after exercise. Interestingly, most of the experiments
that we investigated have been carried out with high-in-
tensity exercise. According to these studies, the actual effect
of exercise on the RANKL/RANK/OPG system needs more
investigations. Regardless, the positive impact of exercises
on bone health and the overall well-being is undeniable.
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